C - Chemistry – Metallurgy – 07 – K
Patent
C - Chemistry, Metallurgy
07
K
C07K 14/54 (2006.01) A61K 38/20 (2006.01)
Patent
CA 2747790
The present invention relates to an Interleukin-21 (IL-21) variant which is capable of increasing the secretion of IgG and/or IgA antibodies in B cells and/or is capable of binding the IL-2 receptor complex and/or the IL-4 receptor complex, comprising stretches of amino acids of Interleukin-4 (IL-4) or interleukin-2 (IL-2) in substitution of amino acids of IL-21. The present invention also relates to a pharmaceutical composition comprising IL- 21 and/or an IL-21 variant and at least one compound selected from IgA inducing protein (IGIP), Syntenin-1, Galectin-1 and Galectin- 3. The present invention further relates to a pharmaceutical composition for the treatment of a primary humoral immunodeficiency disease comprising IL-21 and/or an IL-21 variant and IL-4 and/or IL-2 and/or IGIP and/or Syntenin-1 and/or Galectin-1 and/or Galectin-3. Furthermore the present invention relates to a kit for the treatment of a primary humoral immunodeficiency disease, comprising IL-21 and/or an IL-21 variant and IL-4 and/or IL-2 and/or IGIP and/or Syntenin-1 and/or Galectin-1 and/or Galectin-3 and optionally at least one element selected from a stimulator of CD40 molecules, a ligand of the tumor necrosis superfamily, a polypeptide with human leukocyte interferon activity, a vaccine protein antigen; and a vaccine polysaccharide antigen.
L'invention concerne un variant d'interleukine-21 (IL-21) capable d'augmenter la sécrétion des anticorps IgG et/ou IgA dans des cellules B et/ou de lier le complexe du récepteur d'IL-2 et/ou le complexe du récepteur IL-4, comprenant des fragments d'acides aminés d'interleukine-4 (IL-4) ou d'interleukine-2 (IL-2) en remplacement d'acides aminés de IL-21. L'invention concerne également une composition pharmaceutique comprenant IL-21 et/ou un variant de IL-21 et au moins un composé choisi parmi une protéine induisant IgA (IGIP), Synténine-1, Galectine-1 et Galectine-3. En outre, l'invention concerne une composition pour le traitement d'une maladie d'immunodéficience humorale primaire comprenant IL-21 et/ou un variant de IL-21 et IL-4 et/ou IL-2 et/ou IGIP et/ou Synténine-1 et/ou Galectine-1 et/ou Galectine-3. En outre, l'invention concerne une trousse pour le traitement d'une maladie d'immunodéficience humorale primaire comprenant IL-21 et/ou un variant de IL-21 et IL-4 et/ou IL-2 et/ou IGIP et/ou Synténine-1 et/ou Galectine-1 et/ou Galectine-3 et éventuellement au moins un élément choisi parmi un stimulateur de molécules CD40, un ligand de la superfamille de la nécrose tumorale, un polypeptide avec activité de l'interféron leucocytaire humain, un antigène de protéine vaccin; et un antigène de polysaccharide vaccin.
Borte Stephan
Hammarstrom Lennart
Sack Ulrich
Fraunhofer-Gesellschaft Zur Foerderung Der Angewandten Forschung
Gowling Lafleur Henderson Llp
LandOfFree
Means and method for the treatment of antibody deficiency... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Means and method for the treatment of antibody deficiency..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Means and method for the treatment of antibody deficiency... will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1514693